FP
VIVO

Foundry Partners’s Meridian Bioscience Inc VIVO Stock Holding History

Foundry Partners’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-288,655
Closed -$4.9M – 453
2020
Q3 		$4.9M Buy
+288,655
New +$5.61M 0.24% 134

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Foundry Partners's VIVO Position: Q4 2020 in Review

Foundry Partners sold out of Meridian Bioscience Inc (VIVO) in Q4 2020, closing a stake of 288,655 shares — an estimated $4.9M sold.

Foundry Partners first reported a position in VIVO in Q3 2020 and held it in 1 quarter. The position peaked at $4.9M in Q3 2020. 192 funds tracked by Wall St. Rank hold VIVO as of Q4 2020.

  • Foundry Partners reported no remaining Meridian Bioscience Inc position as of Q4 2020 after selling out during the quarter.
  • Foundry Partners sold 288,655 Meridian Bioscience Inc shares in Q4 2020, an estimated $4.9M.
  • Foundry Partners first reported a position in Meridian Bioscience Inc in Q3 2020 and held it in 1 quarter.
  • Foundry Partners's Meridian Bioscience Inc position peaked at $4.9M in Q3 2020.
  • 192 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2020.

Based on Foundry Partners's 13F filing for Q4 2020, filed 4 Feb 2021.